Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Viola Previtali"'
Autor:
Viola Previtali, Ulrik Bering Keiding, Asger Hegelund Olsen, Jorge Peiró Cadahía, Anne Skovsbo Clausen, Andreas Kjaer, Thomas Lars Andresen, Anders Elias Hansen, Mads Hartvig Clausen
Publikováno v:
European Journal of Medicinal Chemistry Reports, Vol 4, Iss , Pp 100019- (2022)
Tofacitinib (CP-690,550), an approved Janus kinase (JAK) inhibitor, has been proven highly efficacious in treating rheumatoid arthritis (RA). Unfortunately, tofacitinib's clinical application has been limited by adverse side effects that arise from i
Externí odkaz:
https://doaj.org/article/287cda2a79ce492082e2d346cf4a50cb
Autor:
Mads Hartvig Clausen, Asger Hegelund Olsen, Ulrik Bering Keiding, Andreas Kjaer, Jorge Peiró Cadahía, Anders Elias Hansen, Viola Previtali, Anne Skovsbo Clausen, Thomas Lars Andresen
Publikováno v:
Previtali, V, Keiding, U B, Olsen, A H, Peiró Cadahía, J, Clausen, A S, Kjaer, A, Andresen, T L, Hansen, A E & Clausen, M H 2022, ' Synthesis and evaluation of hydrogen peroxide sensitive tofacitinib prodrugs ', European Journal of Medicinal Chemistry Reports, vol. 4, 100019 . https://doi.org/10.1016/j.ejmcr.2021.100019
Tofacitinib (CP-690,550), an approved Janus kinase (JAK) inhibitor, has been proven highly efficacious in treating rheumatoid arthritis (RA). Unfortunately, tofacitinib's clinical application has been limited by adverse side effects that arise from i